FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / Induction of neutralizing antibodies to Hendra and Nipah gly...
Vaccine2010; 29(2); 212-220; doi: 10.1016/j.vaccine.2010.10.053

Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Abstract: The emergence of Hendra Virus (HeV) and Nipah Virus (NiV) which can cause fatal infections in both animals and humans has triggered a search for an effective vaccine. Here, we have explored the potential for generating an effective humoral immune response to these zoonotic pathogens using an alphavirus-based vaccine platform. Groups of mice were immunized with Venezuelan equine encephalitis virus replicon particles (VRPs) encoding the attachment or fusion glycoproteins of either HeV or NiV. We demonstrate the induction of highly potent cross-reactive neutralizing antibodies to both viruses using this approach. Preliminary study suggested early enhancement in the antibody response with use of a modified version of VRP. Overall, these data suggest that the use of an alphavirus-derived vaccine platform might serve as a viable approach for the development of an effective vaccine against the henipaviruses.
Published by Elsevier Ltd.
Get Full Text
Publication Date: 2010-11-02 PubMed ID: 21050901PubMed Central: PMC3032421DOI: 10.1016/j.vaccine.2010.10.053Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study highlights a potential strategy for creating an effective vaccine against Hendra and Nipah viruses by using a vaccine platform derived from Venezuelan equine encephalitis virus.

Objective of the Research

  • The primary goal of this research was to pave the way for an effective vaccine against the Hendra Virus (HeV) and the Nipah Virus (NiV). Both these viruses can cause fatal infections in animals and humans and hence finding a reliable prophylactic measure is essential.

Methodology & Findings

  • The researchers employed an alphavirus-based vaccine platform for this purpose. Specifically, they used Venezuelan equine encephalitis virus replicon particles (VRPs), which were engineered to express HeV and NiV attachment or fusion glycoproteins.
  • These VRPs were then used to immunize groups of mice. The results exhibited a successful induction of robust neutralizing antibodies capable of responding to both HeV and NiV. In immunology, ‘neutralizing antibodies’ refer to those that not only recognize a pathogen but can also block its harmful effects, thus providing immunity.
  • Furthermore, preliminary investigations hinted at an enhanced antibody response with the usage of modified VRPs, suggesting potential improvements in vaccine efficacy.

Conclusion

  • This study’s success potentially indicates that an alphavirus-based vaccine platform could be a promising pathway for procuring an effective vaccine against the henipaviruses (a family of viruses that include Hendra and Nipah Viruses).
  • However, even though these are significant findings, they’re relatively preliminary. More clinical trials testing this vaccine strategy on different animal models and, eventually, in humans, are necessary to prove the safety and efficacy before its dissemination for public use.

Cite This Article

APA
Defang GN, Khetawat D, Broder CC, Quinnan GV. (2010). Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine, 29(2), 212-220. https://doi.org/10.1016/j.vaccine.2010.10.053

Publication

Vaccine
ISSN: 1873-2518
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 29
Issue: 2
Pages: 212-220

Researcher Affiliations

Defang, Gabriel N
  • Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA. gabriel.defang@med.navy.mil
Khetawat, Dimple
    Broder, Christopher C
      Quinnan, Gerald V

        MeSH Terms

        • Animals
        • Antibodies, Neutralizing / blood
        • Antibodies, Viral / blood
        • Encephalitis Virus, Venezuelan Equine / genetics
        • Female
        • Gene Expression
        • Genetic Vectors
        • Hendra Virus / genetics
        • Hendra Virus / immunology
        • Henipavirus Infections / immunology
        • Henipavirus Infections / prevention & control
        • Mice
        • Mice, Inbred C3H
        • Nipah Virus / genetics
        • Nipah Virus / immunology
        • Vaccines, Synthetic / genetics
        • Vaccines, Synthetic / immunology
        • Viral Proteins / genetics
        • Viral Proteins / immunology

        Grant Funding

        • AI037438 / NIAID NIH HHS
        • AI054715 / NIAID NIH HHS
        • U54 AI057168 / NIAID NIH HHS
        • R01 AI054715 / NIAID NIH HHS
        • AI057168 / NIAID NIH HHS
        • R21 AI037438 / NIAID NIH HHS
        • R01 AI037438 / NIAID NIH HHS

        References

        This article includes 60 references
        1. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, Ksiazek TG. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia.. Lancet 1999;354(9186):1257–9.
          pubmed: 10520635
        2. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK. Nipah virus, a newly emergent deadly paramyxovirus.. Science 2000;288:1432–1435.
          pubmed: 10827955
        3. Lam SK, Chua KB. Nipah virus encephalitis outbreak in Malaysia.. Clin Infect Dis 2002;34(2):S48–51.
          pubmed: 11938496
        4. Bishop KA, Broder CC. Hendra and Nipah: Lethal Zoonotic Paramyxoviruses.. In: Scheld WM, Hammer SM, Hughes JM, editors. Emerging Infections. American Society for Microbiology; Washington, D.C: 2008. pp. 155–187.
        5. . NIPAH VIRUS, FATAL - BANGLADESH (DHAKA). Pro-Med International Society for Infectious Diseases; 2008.
        6. . Nipah virus, fatal - Bangladesh: (Faridpur). Pro-MED International Society for Infectious Diseases; 2010.
        7. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR. Person-to-person transmission of Nipah virus in a Bangladeshi community.. Emerg Infect Dis 2007;13(7):1031–7.
          pmc: PMC2878219pubmed: 18214175
        8. Harit AK, Ichhpujani RL, Gupta S, Gill KS, Lal S, Ganguly NK. Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001.. Indian J Med Res 2006;123(4):553–60.
          pubmed: 16783047
        9. Homaira N, Rahman M, Hossain MJ, Epstein JH, Sultana R, Khan MS. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007.. Epidemiol Infect 2010;138(11):1630–6.
          pmc: PMC10071638pubmed: 20380769
        10. Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, Gurley E. Foodborne transmission of Nipah virus, Bangladesh.. Emerg Infect Dis 2006;12(12):1888–94.
          pmc: PMC3291367pubmed: 17326940
        11. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J. The natural history of Hendra and Nipah viruses.. Microbes Infect 2001;3(4):307–14.
          pubmed: 11334748
        12. Westbury HA. Hendra virus disease in horses.. Rev Sci Tech 2000;19(1):151–9.
          pubmed: 11189712
        13. Hanna JN, McBride WJ, Brookes DL, Shield J, Taylor CT, Smith IL. Hendra virus infection in a veterinarian.. Med J Aust 2006;185(10):562–4.
          pmc: PMC7168387pubmed: 17115969
        14. Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008.. Emerg Infect Dis 2010;16(2):219–23.
          pmc: PMC2957996pubmed: 20113550
        15. Chua KB, Koh CL, Hooi PS, Wee KF, Khong JH, Chua BH. Isolation of Nipah virus from Malaysian Island flying-foxes.. Microbes Infect 2002;4(2):145–51.
          pubmed: 11880045
        16. Reynes JM, Counor D, Ong S, Faure C, Seng V, Molia S. Nipah virus in Lyle’s flying foxes, Cambodia.. Emerging Infectious Diseases 2005;11(7):1042–1047.
          pmc: PMC3371782pubmed: 16022778
        17. Wacharapluesadee S, Lumlertdacha B, Boongird K, Wanghongsa S, Chanhome L, Rollin P. Bat Nipah virus, Thailand.. Emerg Infect Dis 2005;11(12):1949–51.
          pmc: PMC3367639pubmed: 16485487
        18. Crameri G, Wang LF, Morrissy C, White J, Eaton BT. A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies.. J Virol Methods 2002;99(1–2):41–51.
          pubmed: 11684302
        19. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P. Nipah Virus: Vaccination and Passive Protection Studies in a Hamster Model.. Journal of Virology 2004;78(2):834–840.
          pmc: PMC368848pubmed: 14694115
        20. Tamin A, Harcourt BH, Ksiazek TG, Rollin PE, Bellini WJ, Rota PA. Functional Properties of the Fusion and Attachment Glycoproteins of Nipah Virus.. Virology 2002;296(1):190–200.
          pubmed: 12036330
        21. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA. Recombinant Nipah Virus Vaccines Protect Pigs against Challenge.. Journal of Virology 2006;80(16):7929–7938.
          pmc: PMC1563797pubmed: 16873250
        22. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.. J Virol 2006;80(24):12293–302.
          pmc: PMC1676295pubmed: 17005664
        23. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.. Virology 1997;239(2):389–401.
          pubmed: 9434729
        24. Johnston RE, Johnson PR, Connell MJ, Montefiori DC, West A, Collier ML. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.. Vaccine 2005;23(42):4969–79.
          pubmed: 16005121
        25. Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses.. Virology 2000;278(1):55–9.
          pubmed: 11112481
        26. Balasuriya UB, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses.. Vaccine 2002;20(11–12):1609–17.
          pubmed: 11858869
        27. Gupta S, Janani R, Bin Q. Characterization of HIV-gag-specific IFNg-expressing cells following protective mucosal immunization with alphavirus replicon particles.. J Virol 2005;79(11):7135–45.
          pmc: PMC1112144pubmed: 15890953
        28. Dong M, Zhang PF, Grieder F, Lee J, Krishnamurthy G, VanCott T. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.. J Virol 2003;77(5):3119–30.
          pmc: PMC149731pubmed: 12584337
        29. Quinnan GV, Zhang PF, Fu DW, Dong M, Alter HJ. Expression and Characterization of HIV Type 1 Envelope Protein Associated with a Broadly Reactive Neutralizing Antibody Response.. AIDS Research and Human Retroviruses 1999;15(6):561–570.
          pubmed: 10221533
        30. Bossart KN, Wang LF, Flora MN, Chua KB, Lam SK, Eaton BT. Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins.. J Virol 2002;76(22):11186–98.
          pmc: PMC136767pubmed: 12388678
        31. Park EJ, Quinnan GV. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.. J Virol 1999;73(7):5707–13.
          pmc: PMC112630pubmed: 10364321
        32. Quinnan GV, Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.. J Virol 2005;79(6):3358–69.
          pmc: PMC1075715pubmed: 15731230
        33. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.. J Virol 2005;79(11):6690–702.
          pmc: PMC1112112pubmed: 15890907
        34. Leavitt M, Park EJ, Sidorov IA, Dimitrov DS, Quinnan GV. Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.. J Virol 2003;77(1):560–70.
          pmc: PMC140585pubmed: 12477860
        35. Park EJ, Gorny MK, Zolla-Pazner S, Quinnan GV. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.. J Virol 2000;74(9):4183–91.
          pmc: PMC111933pubmed: 10756031
        36. Park EJ, Vujcic LK, Anand R, Theodore TS, Quinnan GV. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.. J Virol 1998;72(9):7099–107.
          pmc: PMC109931pubmed: 9696803
        37. Quinnan GV. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response.. AIDS Res Hum Retroviruses 1999;15(6):561–70.
          pubmed: 10221533
        38. Quinnan GV. Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants.. AIDS Res Hum Retroviruses 1998;14(11):939–49.
          pubmed: 9686640
        39. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.. J Virol 2002;76(2):644–55.
          pmc: PMC136808pubmed: 11752155
        40. Zhang PF, Chen X, Fu DW, Margolick JB, Quinnan GV. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.. J Virol 1999;73(6):5225–30.
          pmc: PMC112575pubmed: 10233993
        41. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, Bishop KA. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus.. Proc Natl Acad Sci U S A 2005;102(30):10652–7.
          pmc: PMC1169237pubmed: 15998730
        42. Bossart KN, Broder CC. Viral Glycoprotein-Mediated Cell Fusion Assays Using Vaccinia Virus Vectors.. Methods Mol Biol 2004;269:309–332.
          pubmed: 15114023
        43. Bossart KN, Mungall BA, Crameri G, Wang LF, Eaton BT, Broder CC. Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.. Virol J 2005;2:57.
          pmc: PMC1208959pubmed: 16026621
        44. Nussbaum O, Broder CC, Berger EA. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.. Journal of Virology 1994;68(9):5411–5422.
          pmc: PMC236941pubmed: 8057423
        45. Berger EA, Nussbaum O, Broder CC. HIV envelope glycoprotein/CD4 interactions: studies using recombinant vaccinia virus vectors.. HIV: a practical approach 1995;2:123–145.
        46. Broder CC, Berger EA. Fusogenic Selectivity of the Envelope Glycoprotein is a Major Determinant of Human Immunodeficiency Virus Type 1 Tropism for CD4+ T-Cell Lines vs. Primary Macrophages.. Proceedings of the National Academy of Sciences 1995;92(19):9004–9008.
          pmc: PMC41096pubmed: 7568061
        47. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know.. Nature Medicine 2004;10:806–810.
          pubmed: 15286782
        48. Griffin DE. Immune responses during measles virus infection.. Curr Top Microbiol Immunol 1995;191:117–34.
          pubmed: 7789155
        49. Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.. J Virol 2006;80(2):891–9.
          pmc: PMC1346873pubmed: 16378991
        50. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats.. Vaccine 2008;26(31):3842–3852.
          pmc: PMC6186147pubmed: 18556094
        51. Charles PC, Brown KW, Davis NL, Hart MK, Johnston RE. Mucosal Immunity Induced by Parenteral Immunization with a Live Attenuated Venezuelan Equine Encephalitis Virus Vaccine Candidate.. Virology 1997;228(2):153–160.
          pubmed: 9123821
        52. Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins.. Virology 1995;206(2):994–1006.
          pubmed: 7856110
        53. Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.. Journal of Virology 1996;70(6):3781–3787.
          pmc: PMC190254pubmed: 8648713
        54. Davis NL, Caley J, Brown KW, Betts MR, Irlbeck DM, McGrath KM. Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles.. Journal of Virology 2000;74(1):371–378.
          pmc: PMC111548pubmed: 10590126
        55. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.. Vaccine 2000;19(1):142–53.
          pubmed: 10924796
        56. Kinney RM, Esposito JJ, Mathews JH, Johnson BJ, Roehrig JT, Barrett AD. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.. Journal of Virology 1988;62(12):4697–4702.
          pmc: PMC253584pubmed: 3184276
        57. Jahrling PB, Stephenson EH. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters.. Journal of Clinical Microbiology 1984;19(3):429–431.
          pmc: PMC271080pubmed: 6715512
        58. Baker KA, Dutch RE, Lamb RA, Jardetzky TS. Structural basis for paramyxovirus-mediated membrane fusion.. Mol Cell 1999;3(3):309–319.
          pubmed: 10198633
        59. Brideau RJ, Oien NL, Lehman DJ, Homa FL, Wathen MW. Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein.. Journal of General Virology 1993;74(3):471–477.
          pubmed: 8383179
        60. Drillien R, Spehner D, Kirn A, Giraudon P, Buckland R, Wild F. Protection of Mice from Fatal Measles Encephalitis by Vaccination with Vaccinia Virus Recombinants Encoding Either the Hemagglutinin or the Fusion Protein.. Proceedings of the National Academy of Sciences 1988;85(4):1252–1256.
          pmc: PMC279745pubmed: 3422488
        Subscribe to our newsletter
        Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.